MOTS-C (mitochondrial open reading frame of the twelve S rRNA type-C) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. Discovered in 2015 by the Lee laboratory at USC (Lee, Zeng, Drew, Sallam and colleagues, Cell Metabolism 2015), it was one of the first mitochondrial-genome-encoded peptides identified in human biology after humanin (Hashimoto/Nishimoto group, 2001). The peptide signals from mitochondria to the nucleus through AMP-activated protein kinase (AMPK).

What does MOTS-C do mechanistically?

MOTS-C activates the AMPK metabolic-sensing pathway through inhibition of the folate-methionine cycle. The pathway is: MOTS-C → folate-cycle inhibition → AICAR accumulation → AMPK activation → metabolic-axis output. Downstream AMPK activation drives glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis — the same downstream pathway activated by caloric restriction, exercise, and metformin.

What has MOTS-C been shown to do in research?

Published animal-model research reports four categories of effect: improved glucose tolerance and insulin sensitivity in metabolic-syndrome models, increased exercise capacity and skeletal-muscle mitochondrial biogenesis, reduced fat mass with preserved lean mass, and improvement in lifespan-associated markers. Human interventional research is at an earlier stage than the animal-model evidence.

How does MOTS-C differ from SS-31?

Both are mitochondria-related research peptides but target different aspects of mitochondrial biology. MOTS-C is encoded in mitochondrial DNA and signals to the nuclear compartment through AMPK — it is an inter-organelle signalling molecule. SS-31 is a synthetic membrane-binding peptide that stabilises cristae structure at the inner mitochondrial membrane through cardiolipin binding. Different mechanisms, different research questions.

Research · MOTS-C

MOTS-C — the mitochondrial-derived 16-residue peptide

Creator: Wellness Labs Editorial
Published: 2026-06-02
Keywords: mots-c uae, mots-c uae, mots-c dubai, mots-c peptide, mitochondrial peptide, mots-c research, mots-c mechanism, ampk peptide, mots-c exercise

Wellness Labs Editorial·2 June 2026·6 min read

Medically reviewed by

Wellness Labs Research Team · Research and Editorial

Last reviewed 1 June 2026

MOTS-C (mitochondrial open reading frame of the twelve S rRNA type-C) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — one of the first mitochondrial-genome-encoded peptides identified in human biology. Discovered in 2015 by the Lee laboratory at USC, MOTS-C signals from mitochondria to the nuclear compartment through AMP-activated protein kinase (AMPK) and is the subject of active research in metabolic regulation, exercise physiology, and age-related metabolic decline.

Discovery and the mitochondrial-encoded-peptide concept

MOTS-C was first reported in 2015 by the Lee laboratory at USC (Lee, Zeng, Drew, Sallam and colleagues, Cell Metabolism 2015). The discovery was surprising at the time: the conventional view of the mitochondrial genome was that it encodes 13 proteins (all subunits of the electron-transport chain), 22 tRNAs, and 2 rRNAs — and that was the complete list. MOTS-C is encoded within the 12S ribosomal RNA gene, in a small open reading frame embedded inside the rRNA sequence. The discovery established the existence of mitochondrial-derived peptides (MDPs) as a distinct biological signalling class.

A handful of related mitochondrial-derived peptides have been identified since: humanin (encoded within the 16S rRNA gene, the first MDP discovered, originally reported in 2001 by the Hashimoto/Nishimoto group at Keio University), the SHLPs (small humanin-like peptides), and several short open reading frames in mitochondrial DNA whose translation products are still being characterised. MOTS-C remains the most-studied MDP in metabolic-regulation research.

Sequence and structure

The MOTS-C sequence is Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (16 amino acids). Molecular weight is approximately 2,174 Da. The peptide is translated from the mitochondrial 12S rRNA short open reading frame, exported from the mitochondrion to the cytosol, and from there into circulation, where it functions as an inter-organelle and inter-tissue signalling molecule.

Endogenous plasma MOTS-C concentrations decline measurably with age in both rodents and humans. The decline correlates with metabolic-decline markers (insulin resistance, reduced exercise capacity, mitochondrial-function decline). Whether the decline is causally upstream of the metabolic changes, or downstream of them, or both, is one of the open research questions.

AMPK-pathway mechanism

The defining mechanistic finding for MOTS-C is activation of the AMP-activated protein kinase (AMPK) pathway. AMPK is the cellular energy-sensing kinase — it activates when ATP is low and AMP is high, triggering catabolic processes (glucose uptake, fatty-acid oxidation, mitochondrial biogenesis) and inhibiting anabolic processes (protein synthesis, fatty-acid synthesis). Activated AMPK is downstream of caloric restriction, intense exercise, and metformin — three of the most-studied longevity-and-metabolic-research interventions.

MOTS-C activates AMPK indirectly, through inhibition of the folate-methionine cycle. The mechanism involves binding to nuclear factors that regulate one-carbon metabolism, with downstream effects on AICAR (an AMP analogue) accumulation, which in turn activates AMPK. The pathway is therefore: MOTS-C → folate-cycle inhibition → AICAR accumulation → AMPK activation → metabolic-axis output.

Honest take: the MOTS-C → AMPK linkage has been replicated across multiple laboratories and is the strongest part of the mechanism story. The specific upstream binding interactions (which nuclear factors, which folate-cycle steps) are still being mapped.

Published research findings

Published research in animal models has reported MOTS-C effects across four categories:

Insulin sensitivity and glucose homeostasis. MOTS-C administration improves glucose tolerance and insulin sensitivity in high-fat-diet-induced metabolic-syndrome rodent models. The effect is consistent with the AMPK-mediated mechanism (AMPK drives skeletal-muscle glucose uptake).
Exercise capacity and skeletal-muscle adaptation. MOTS-C treatment increases exercise capacity in older rodents to levels approaching young controls. Skeletal-muscle mitochondrial biogenesis markers (PGC-1α, citrate synthase activity) are upregulated.
Fat-mass and lean-mass distribution. Reduced fat mass and preserved lean mass in metabolic-syndrome models, even without dietary intervention. The effect is moderate in magnitude, consistent with the AMPK-mediated catabolic-pathway activation.
Lifespan markers. Reported increase in markers associated with longer healthspan in invertebrate and rodent models, including reduced expression of inflammaging markers.

Human clinical research is at an earlier stage than the animal-model evidence base. Observational studies of endogenous MOTS-C plasma concentrations correlate higher levels with better metabolic-health markers in healthy adults. Interventional studies of exogenous MOTS-C administration in humans are limited.

Current research-use protocols

Published animal-model research protocols use MOTS-C administered by intraperitoneal or subcutaneous injection. Doses range 0.1-1.0 mg/kg/day in rodent work, scaled to the research question. Plasma half-life is short (~1-2 hours); tissue uptake (especially skeletal muscle and liver) is the relevant pharmacokinetic parameter.

Research-protocol durations range from acute single-dose pharmacokinetic studies to chronic 4-12 week intervention studies. The longer-duration protocols are appropriate for the body-composition and exercise-capacity endpoints, where adaptation timescales are weeks.

UAE research-supply landscape

MOTS-C is supplied in the UAE as lyophilised research-grade powder. Wellness Labs catalogues MOTS-C in 10 mg and 20 mg vials in the Longevity group, alongside the other mitochondrial-research compounds. Quality verification: third-party RP-HPLC purity ≥98%, mass-spectrometry parent-ion confirmation at ~2,174 Da, batch-traceable Certificate of Analysis.

Reconstitution math

10 mg / 2 mL bacteriostatic water = 5 mg/mL = 5000 μg/mL. A 500 μg dose is 0.1 mL = 10 units; a 1 mg dose is 0.2 mL = 20 units.
20 mg / 4 mL bacteriostatic water = 5 mg/mL. Same per-dose unit math as 10 mg vial — convenient for longer protocols.
20 mg / 2 mL bacteriostatic water = 10 mg/mL. Smaller-volume draws when high-concentration solution is preferred.

Open research questions

Whether the AMPK-pathway activation in rodent models translates to comparable magnitudes in human metabolic-disease research.
The optimal exogenous administration protocol — daily SC vs less-frequent dosing — given the short plasma half-life but longer tissue residence.
Whether MOTS-C combined with exercise produces additive metabolic-axis effects, or whether endogenous exercise-induced MOTS-C production already saturates the pathway.

Frequently asked questions

What is MOTS-C?: MOTS-C (mitochondrial open reading frame of the twelve S rRNA type-C) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. Discovered in 2015 by the Lee laboratory at USC (Lee, Zeng, Drew, Sallam and colleagues, Cell Metabolism 2015), it was one of the first mitochondrial-genome-encoded peptides identified in human biology after humanin (Hashimoto/Nishimoto group, 2001). The peptide signals from mitochondria to the nucleus through AMP-activated protein kinase (AMPK).
What does MOTS-C do mechanistically?: MOTS-C activates the AMPK metabolic-sensing pathway through inhibition of the folate-methionine cycle. The pathway is: MOTS-C → folate-cycle inhibition → AICAR accumulation → AMPK activation → metabolic-axis output. Downstream AMPK activation drives glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis — the same downstream pathway activated by caloric restriction, exercise, and metformin.
What has MOTS-C been shown to do in research?: Published animal-model research reports four categories of effect: improved glucose tolerance and insulin sensitivity in metabolic-syndrome models, increased exercise capacity and skeletal-muscle mitochondrial biogenesis, reduced fat mass with preserved lean mass, and improvement in lifespan-associated markers. Human interventional research is at an earlier stage than the animal-model evidence.
What dose is used in MOTS-C research?: Published animal-model protocols use 0.1-1.0 mg/kg/day by subcutaneous or intraperitoneal injection in rodent work. Plasma half-life is short (~1-2 hours); tissue uptake (especially skeletal muscle and liver) is the relevant pharmacokinetic parameter. Reconstitution from a 10 mg vial typically uses 2 mL bacteriostatic water (5 mg/mL).
How does MOTS-C differ from SS-31?: Both are mitochondria-related research peptides but target different aspects of mitochondrial biology. MOTS-C is encoded in mitochondrial DNA and signals to the nuclear compartment through AMPK — it is an inter-organelle signalling molecule. SS-31 is a synthetic membrane-binding peptide that stabilises cristae structure at the inner mitochondrial membrane through cardiolipin binding. Different mechanisms, different research questions.
Where can I source MOTS-C in the UAE?: Wellness Labs supplies MOTS-C in 10 mg and 20 mg lyophilised vials as research-grade material. Quality criteria: third-party RP-HPLC purity ≥98%, mass-spectrometry parent-ion confirmation at ~2,174 Da, batch-traceable Certificate of Analysis. The compound is research-use only; not approved for clinical use in any jurisdiction.